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A B S T R A C T
Thymulin is a thymic peptide possessing anti-inflammatory effects. In order to manipulate thymulin expression
in gene therapy studies, we built a bidirectional regulatable two-vector Tet-Off system and the corresponding
control system. The experimental two-vector system, ETV, consists of a recombinant adenovector (RAd)
harboring an expression cassette centered on a Tet-Off bidirectional promoter flanked by a synthetic gene for
thymulin and the gene for humanized Green Fluorescent Protein (hGFP). The second adenovector of this system,
RAd-tTA, constitutively expresses the regulatory protein tTA. When cells are co-transduced by the two
adenovector components, tTA activates the bidirectional promoter and both transgenes are expressed. In the
presence of the antibiotic doxycycline (DOX) transgene expression is deactivated. The control two-vector system,
termed CTV, is similar to ETV but only expresses hGFP. In CHO-K1, BHK, and C2C12 cells, ETV and CTV induced
a dose-dependent hGFP expression. In CHO-K1 cells, transgene expression was almost completely inhibited by
DOX (1 mg/ml). After intracerebroventricular injection of ETV in rats, thymulin levels increased significantly in
the cerebrospinal fluid and there was high hGFP expression in the ependymal cell layer. When injected
intramuscularly the ETV system induced a progressive increase in serum thymulin levels, which were inhibited
when DOX was added to the drinking water. We conclude that our regulatable two-adenovector system is an
effective molecular tool for implementing short and long-term anti-inflammatory thymulin gene therapy in
animal models of acute or chronic inflammation.
1. Introduction
Thymulin is a thymic hormone that participates in several aspects of
intra- and extrathymic T-cell differentiation (Bach 1983). Thymulin is
produced by the thymic epithelial cells (Dardenne et al., 1974) and
consists of an inactive peptide component termed FTS (a French
acronym for serum thymus factor), coupled in an equimolecular ratio
to the ion zinc (Gastinel et al., 1984), which confers biological activity
to the peptide (Dardenne et al., 1982). The metallopeptide active form
is characterized by a specific molecular conformation that has been
determined by nuclear magnetic resonance (Cung et al., 1988). There is
a growing body of evidence that, in addition to its immunomodulatory
actions, thymulin possesses hypophysiotropic activity (Goya et al.,
2004). An adenovector expressing a synthetic gene for the thymulin
analog methionine-FTS (metFTS), constructed by us, was shown to
induce long-term expression of transgenic thymulin in serum when
intramuscularly (i.m.) injected in rodents (Reggiani et al., 2006).
Moreover, using this vector we demonstrated that neonatal thymulin
gene therapy is able to prevent the typical ovarian dysgenesis that
occurs in congenitally athymic nude female mice after puberty
(Reggiani et al., 2012) and restores their deficient gonadotropin serum
levels (Goya et al., 2007). More recent reports revealed an anti-
inflammatory activity of thymulin in the brain and other organs, which
makes thymulin a molecule of clinical interest. Among the immune
factors that interact with thymulin are a set of cytokines that play a
major role in the inflammatory response. In a model of endotoxin-
induced neuroinflammation, prior intracerebroventricular (i.c.v.) injec-
tions with thymulin (0.1–1 μg) prevented the endotoxin-induced hy-
peralgesia and exerted differential effects on the up-regulated levels of
cytokines in different regions of the central nervous system (CNS),
suggesting a neuroprotective role of thymulin in the brain (Safieh-
Garabedian et al., 2003). A thymulin analog also induced a significant
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amelioration of endotoxin-induced hyperalgesia and a decrease in the
release of the proinflammatory cytokines IL-1ß, IL-6, and TNFα in the
hippocampus and brainstem. Injected alone, the analog induced an up-
regulation of IL-10 in the hippocampus and brainstem and produced a
marked enhancement of the level of this cytokine in the same areas
when endotoxin was simultaneously applied (Safieh-Garabedian et al.,
2011). A beneficial action of thymulin was also reported in a number of
models of organ-specific inflammation: In alloxan- and streptozotocin-
induced diabetes, pretreatment with thymulin significantly suppressed
hyperglycemia and prevented the destruction of pancreatic beta cells
(Yamanouchi et al., 1994). A similar protection was reported in
myocarditis induced by encephalomyocarditis virus and in pulmonary
hypertension induced by monocrotaline (Henriques-Coelho et al.,
2008). In the latter model, thymulin effect was related to the inhibition
of the expression of the proinflammatory cytokine IL-6 and to the
suppression of the p38 MAPK pathway. In a more recent report, Da
Silva et al. (2014) implemented thymulin gene therapy in a mouse
model of allergic asthma. In this study, intratracheal injection of a
nanoparticle-complexed plasmid expressing our synthetic gene for
thymulin decreased lung eosinophil infiltration, IL-13, eotaxin, trans-
forming growth factor-β, vascular endothelial growth factor, and
increased lung interferon-γ. The changes were paralleled by a reduction
in the fraction area of alveolar collapse, bronchoconstriction index,
smooth-muscle-specific actin expression, collagen fiber content in the
airway and alveolar septa and airway hyperresponsiveness. This study
revealed that DNA-nanoparticle-mediated thymulin gene therapy can
modulate the inflammatory and remodeling processes in experimental
allergic asthma, therefore improving lung mechanics. The thymulin
plasmid used in the above study (Da Silva et al., 2014) revealed the
suitability of thymulin vectors for the treatment of inflammatory
pathologies. We reasoned that a viral vector expressing thymulin and
a reporter gene both under the control of a bidirectional regulatable
promoter would allow experimenters, and eventually clinical gene
therapists, to manipulate the expression of these genes according to
treatment needs. Capitalizing on our expertise in the molecular biology
of thymulin we decided to construct such a vector. In the present study,
we report its construction and both an in vitro and in vivo characteriza-
tion of a bidirectional regulatable two-adenovector Tet-Off system
expressing humanized GFP (hGFP) and our synthetic gene for thymulin
(metFTS).
2. Materials and methods
2.1. Construction of a regulatable bidirectional two-adenovector system
2.1.1. Construction of shuttle plasmid pDC516-(GFP-TRE-FTS)
A variant of our synthetic gene metFTS was constructed (Reggiani
et al., 2006), which contained the restriction endonuclease (RE) sites
MluI and EcorRV in its 5′ and 3′ regions, respectively. This insert was
then cloned into the Multiple Cloning site I (MCS I) of the pBI Tet-Off
vector (Clontech (Takara), Mountain View, CA), a bidirectional expres-
sion vector harboring the regulatable TRE element flanked by two
minimal Cytomegalovirus Promoters (PminCMV) positioned in opposite
orientations. Afterwards, the hGFP cDNA was inserted into the MCS II
of the above mentioned plasmid in the NotI restriction site. This step
was checked for correct orientation by means of restriction mapping.
The resulting plasmid was named pBI-(GFP-TRE-FTS). Therefrom, the
cassette GFP-TRE-FTS was excised with the REs SalI and BglII and
cloned into the corresponding restriction sites of the plasmid
pDC516w/p, a modified version of pDC516 (Microbix Biosystems
Inc., Mississauga, Canada) by excising its promoter but keeping the
polyadenylation signal SV40 pA. In order to provide the second
polyadenylation signal to this construct, a DNA fragment coding for
the SV40 pA, flanked by the restriction sites for XhoI and XbaI, was
inserted into the corresponding restriction sites of our plasmid. The
final construct was named pDC516-(GFP-TRE-FTS), which harbors the
regulatable bidirectional cassette and the SV40 pA signal downstream
both transgenes. The control plasmid, named pDC516-(GFP-TRE-MCS),
was constructed following the same procedure, except that the MCS I
was left empty, which resulted in a final plasmid only expressing hGFP.
2.1.2. Construction of shuttle plasmid pDC515-tTA
In order to construct this plasmid, the DNA sequence coding for the
regulatory protein tTA was excised from plasmid pTet-Off (Clontech)
into the MCS of the shuttle plasmid pDC515 (Microbix Biosystems Inc.)
by using the REs EcoRI and BamHI.
2.1.3. Generation of recombinant adenoviral vectors (RAd)
RAds were constructed by a variant of the two plasmid method (Hitt
et al., 1998) employing the AdMax® plasmid kit (Microbix, Canada) as
described elsewhere (Reggiani et al., 2006). Briefly, the kit uses a
shuttle plasmid (pDC515 or pDC516) harboring a MCS and FRT
recognition sequences for the yeast FLP recombinase. The cassette is
flanked by the sequences of the adenovirus type 5 (Ad5) E1 region. The
second plasmid of the kit, the genomic plasmid pBHGfrt(del)E1,3FLP,
consists of the entire genome of Ad5, containing deletions in the regions
E1 and E3. Upstream the E1 deletion, this plasmid contains an
expression cassette harboring the gene for yeast FLP recombinase and
immediately downstream the E1 deletion, a FRT recognition site. In
order to generate the two RAds of our two-adenovector system, the
genomic plasmid was cotransfected with either shuttle pDC516-(GFP-
TRE-FTS) or shuttle pDC515-tTA in Human Embryonic Kidney 293
(HEK293) cells. In cotransfected HEK293 cells, the FLP recombinase is
expressed and catalyzes a site-directed recombination of the expression
cassette of pDC516-(GFP-TRE-FTS), pDC516-(GFP-TRE-MCS) or
pDC515-tTA into the left end of pBHGfrt(del)E1,3FLP, thus generating
the genome of the desired recombinant adenoviral vectors. The newly
generated RAds, termed RAd-(GFP-TRE-FTS), RAd-(GFP-TRE-MCS)
and RAd-tTA were rescued from HEK293 cell lysates and plaque
purified. They were further purified by ultracentrifugation in CsCl
gradient. Final virus stocks were titrated by a serial dilution plaque
assay.
2.2. In vitro characterization of the system
2.2.1. Optimization of the MOI
In order to evaluate the performance of the regulatable bidirectional
two-adenovector system in vitro, we assessed the expression of the
reporter gene hGFP at several MOIs in the following cell lines: mouse
muscle myoblasts C2C12, rat glial B92 cells and Chinese hamster ovary
(CHO-KI) cells. These cell lines were used and maintained as recom-
mended by the American Type Culture Collection (ATCC). The MOIs
(pfu/cell) 0, 12, 36, 100, 500 and 1000, were tested in triplicate for the
experimental two-vector system (ETV: RAd-(GFP-TRE-FTS) + RAd-
tTA) and the control two-vector system (CTV: RAd-(GFP-TRE-MCS)
+ RAd-tTA). In every case, equal ratios of the RAd-tTA and RAd ETV/
CTV vectors were used. On experimental day−1, 1.6 × 105 cells were
seeded on 24-well plates. On day 0 virus transduction for each cell line
was performed in Fetal Bovine Serum (FBS)-free medium for 1.5 h,
rocking the plate every 15 min. Afterwards, the medium was replaced
by 500 μl maintenance medium, which was kept until the end of the
experiment. On day 2, microphotographs of the cultures were taken and
cells were lysed in order to quantitate GFP expression as described in
Section 2.4.2.
2.2.2. Characterization of system regulatability
In order to assess in vitro the regulatability of the system by
doxycycline (DOX), CHO-KI cells were used. On experimental day −1
cells were seeded on 12-well plates and, when appropriate, DOX
(Clontech) was added to the culture media at a concentration of 1
ug/ml. On day 0, culture medium was replaced by, a) culture medium
as a negative control for virus transduction, b) RAd-tTA and RAd-(GFP-
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TRE-FTS) in culture medium as a positive control for baseline hGFP
expression, c) RAd-tTA and RAd-(GFP-TRE-FTS) in medium containing
DOX to assess regulatability of the system and, d) RAd-(GFP-TRE-FTS)
alone in culture medium as negative control for the two-vector system
functionality. In every case we used a MOI = 200 for each adenovector.
On day 2, micrographs were taken in order to observe hGFP fluores-
cence, supernatant was collected to determine thymulin and cells were
lysed to quantify GFP fluorescence.
2.3. Animals and in vivo procedures
Young (4–9 week) C57BL/6 male and female mice as well as three-
month-old Sprague Dawley male rats were raised in our animal facilities
(INIBIOLP). Animals had free access to food and water and were kept at
22 °C with a light/dark cycle of 12/12 h. All experiments with animals
were done following the Animal Welfare Guidelines of NIH (INIBIOLP’s
Animal Welfare Assurance No A5647-01) and in conformity with the
Guidelines on Handling and Training of Laboratory Animals published
by the Universities Federation for Animal Welfare (The Biological
Council Animal Research and Welfare Panel (Eds.), UFAW, Pert,
1992). The corresponding protocol was approved by our Institutional
Animal Welfare Committee, IACUC protocol # P05-02-2015, 9th
October, 2015.
2.3.1. Transgene expression in skeletal muscle
On experimental day −14 rats were thymectomized and divided
into two groups (N = 4/group): CTV and ETV. On experimental day 0,
following the procedure described in Section 2.3.5.2, they received
0.1 ml of a suspension containing 1 × 108 plaque forming units (pfu) of
each virus component of CTV or ETV, according to the experimental
group. In order to assess serum thymulin levels, blood was withdrawn
every 7 days as described in Section 2.3.5.4. On day 2, one experi-
mental subject from each group was euthanized to observe hGFP
fluorescence (see Section 2.3.5.5). The remainder of the animals was
euthanized on post vector injection day 49.
2.3.2. Thymulin expression regulatability in skeletal muscle
The animals were divided into two groups (N = 5/group): CTV and
ETV. On day 0 they were injected as described in Section 2.3.5.2.
Afterwards, blood was withdrawn every 5 days from their tail veins
until day 25 in order to assess serum thymulin levels. On day 15 DOX
was added to the drinking water at a final concentration of 2 mg/ml.
This preparation was renewed every 2 days until the end of the
experiment. On experimental day 20 the drinking water of the rats
was supplemented with β-methasone at a final concentration of 15 mg/
l. The aim of this corticoid addition was to pharmacologically inhibit
endogenous thymulin secretion from the thymus (Goya et al., 2003).
2.3.3. Transgene expression in the brain
Animals were divided into two groups (N = 4/group): CTV and
ETV. Following the procedure described in Section 2.3.5.3, they were
injected in each LV 10 μl of a suspension containing 1 × 109 pfu of each
virus component of the CTV and ETV systems. Seventy-two h later, CSF
was obtained as described in Section 2.3.5.4 to assess thymulin levels.
Immediately afterwards, animals were transcardially perfused and their
brains processed for fluorescence microscopy as described in Section
2.3.5.6. CSF samples were stored at −80 °C.
2.3.4. Time course of hGFP expression in the cerebral ventricles
The duration of hGFP expression in the ependymal layer of
thymectomized animals i.c.v. injected with ETV (N = 15) was mon-
itored. After performing i.c.v. injection, three rats were euthanized on
experimental days 2, 7, 14, 21 and 28. Their brains were processed for
fluorescence microscopy and micrographs taken as described in Section
2.3.5.6.
2.3.5. Surgical and histological procedures
2.3.5.1. Thymectomy (Tx). Tx in rats was performed as previously
described (Waynforth and Flecknell, 1992). Tx in mice was performed
by aspiration with the animals under Avertin (2,2,2 tribromoethanol)
anesthesia (0.4 mg/g BW, i.p.). In order to ensure the absence of
circulating thymulin, Tx animals were studied 14 days after surgery.
2.3.5.2. Skeletal muscle injections. Animals were anesthetized with
2–3% isoflurane at flow rate of 1.5 l/min oxygen and positioned
ventrally on the operating table with both hindlimbs extended and
gently immobilized. The hair was shaved from the skin covering the
tibialis anterior (TA) muscles of both legs; the skin disinfected with
topic povidone-iodine and finally a 1-cm long incision was made to
access the muscular compartment. The TA muscle of their hindlimbs
was identified and 100 μl vector was injected in its middle portion.
2.3.5.3. Stereotaxic injections. I.c.v. injections were performed as
previously described (Pardo et al., 2016). Briefly, rats were
anesthetized with ketamine hydrochloride (40 mg/kg; i.p.) plus
xylazine (8 mg/kg; i.m.) and placed on a stereotaxic apparatus.
Injections in the lateral ventricles (10 μl vector suspension, per side)
were performed by placing the tip of a Hamilton syringe needle at the
following coordinates relative to the bregma: −0.8 mm
anteroposterior, 4.1 mm dorsoventral and± 1.5 mm mediolateral
(Paxinos and Watson, 1998).
2.3.5.4. Blood and CSF collection. At different times, animals were
isoflurane anesthetized and their tails immersed in 42 °C water for
40–50 s to dilate blood vessels. The tail vein to be bled was located and
punctured with a 22G needle and 2 ml blood was collected using a Kahn
tube. Before sacrifice, CSF was obtained from the great cerebral cistern
by puncture as previously documented (Nishida et al., 2011). Briefly,
rats were anesthetized with ketamine-xylazine and CSF withdrawn with
a syringe fitted to a 30G needle. With this procedure it was possible to
obtain 50–100 μl CSF.
2.3.5.5. Muscle processing. Two days after transduction with our two-
vector system, rats were euthanized and the TA muscles were promptly
dissected, fixed with phosphate buffered paraformaldehyde 4% (4% PB-
PFA) for 48 h at 4 °C and cryopreserved (30% sucrose in 4% PB-PFA)
for 3 days at−20 °C. Finally, muscles were embedded in tissue-freezing
medium (Cryoplast®, Biopack, Buenos Aires, Argentina) and stored at
−80 °C until further processing. Longitudinal 30-μm thick sections
were obtained with a freezing microtome (Leitz 1320, Wetzlar,
Germany) and mounted with fluorescent mounting medium
(Fluoromount G™, Electron Microscopy Sciences, PA, USA).
2.3.5.6. Brain processing. Animals were placed under deep anesthesia
and perfused with 4% PB-PFA (pH 7.4) fixative. The brains were
removed and post-fixed in 4% PB-PFA overnight at 4 °C. Brains were
processed for fluorescence microscopy as described elsewhere (Pardo
et al., 2016). To obtain fluorescence images, coverslips were covered
with Fluoromount G and mounted onto the slides.
2.4. hGFP expression
2.4.1. hGFP fluorescence image acquisition
Cell culture images were acquired with an Olympus Digital Camera
E-330 attached to Olympus IX-71 inverted fluorescence microscope,
whereas hGFP expression in muscle and brain tissue was assessed with
an Olympus BX51 microscope equipped with a DP70 CCD Video
Camera. The subsequent image processing was performed with
(Image-Pro® Plus) software (Version 5.1.2, Media Cybernetics, Inc).
2.4.2. hGFP quantification in cell lysates
Cell lysates were collected from 24-well plates as follows: after
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culture medium was removed, the monolayer was rinsed three times
with phosphate buffered saline (PBS) and then incubated with 150 μl/
well lysis buffer (0.1%, Tritón X-100, 1 mM EDTA in PBS), for 30 min at
4 °C. Afterwards, the lysates were collected and centrifuged for 1 min at
13,000 rpm. Then, 100 μl/well clean supernatant was added in a Nunc™
MicroWell™ 96-Well Optical-Bottom Plates with Polymer Base (Catalog
#:265301, Thermo Scientific™). Fluorescence intensity was subse-
quently measured in a multimode microplate reader (Beckman
Coulter® DTX 880 Multimode Detector) at excitation and emission filter
(nm) of 485 SL 1 and 535 SL 1, respectively. The results were expressed
as arbitrary fluorescence units.
2.5. Thymulin bioassay
Biologically active thymulin was measured in cell cultures and
serum by a rosette bioassay described in detail elsewhere (Dardenne
and Bach, 1975). This method is based on the ability of thymulin to
restore the inhibitory effect of azathioprine (Az) on rosette formation in
spleen cells from Tx mice. Briefly, sera or supernatants were filtered
through membranes (30 kDa cut-off; YMT micropartition system, PMS-I
Amicon Corporation, Denver) and the ultrafiltrates were diluted serially
and incubated for 90 min at 37 °C with spleen cells from C57BL/6 Tx
mice in the presence of 10 μg Az/ml, which is a concentration that
inhibits 50% rosette formation in normal but not thymectomized mice.
Rosettes were then allowed to form by centrifugation with sheep red
blood cells and counted in a hemacytometer after gentle resuspension.
Rosette formation was inhibited by thymulin in a dose-dependent
manner. The inhibitory activity of samples was compared with that of
a standard curve using synthetic thymulin (a kind gift from P.
Heinklein, Humboldt University, Berlin). Values were expressed as
bioactive thymulin concentration in the sample. The sensitivity of the
assay is 1 fg thymulin/ml.
2.6. Statistical analysis
All data are expressed as mean ± SEM (standard error of the
mean). Comparisons between experimental groups were done by
unpaired Student's t-test or ANOVA followed by Dunnett, Tukey’s or
Sidak tests.
3. Results
3.1. Structure and function of the two-adenovector system for hGFP and
thymulin
We constructed a two-adenovector system based on the transactiva-
tion of the bidirectional expression cassette GFP-TRE-FTS by the
regulatory protein tTA that binds to the TRE element of the bidirec-
tional promoter PminCMV-TRE-PminCMV, almost inactive per se, and
fully activates the expression of the FTS and hGFP transgenes (Fig. 1A).
When DOX is added to the system the antibiotic binds to an allosteric
site of the tTA protein inducing a conformational change that causes a
loss of affinity of tTA for the TRE element. Thus, the tTA protein
dissociates from the promoter, which becomes inactive (Fig. 1B). By
themselves RAd-(GFP-TRE-FTS), RAd-(GFP-TRE-MCS), and RAd-tTA
are inactive concerning transgene expression.
3.2. Characterization of the system in vitro
3.2.1. Optimization of the multiplicity of infection (MOI)
The MOI-dependent hGFP expression of the ETV and CTV systems
was assessed in three cell lines: CHO-KI, B92 and C2C12. CHO-K1 cells
were the most receptive to virus transduction followed by B92 cells.
C2C12 cells were less amenable to transduction. This is in line with
previous reports stating that C2C12 myoblasts express low levels of the
primary Ad membrane receptor (Kimura et al., 2001). In CHO-KI and
B92 cells, transduction levels were low up to MOI 36 but increased
significantly from MOI 100 (Fig. 2). In contrast, C2C12 cells showed a
substantial increase starting from MOI 500.
3.2.2. Thymulin and hGFP regulatability in cultures
The DOX-dependent regulatability of the ETV system was studied.
In CHO-KI cell cultures DOX (1 mg/ml) induced a complete inactivation
of the bidirectional Tet-Off promoter as shown by the almost complete
disappearance of thymulin from the cell supernatants and hGFP
fluorescence from the cell lysates (Fig. 3, upper and lower panels,
respectively). As expected, RAd-(GFP-TRE-FTS) alone was inactive.
3.3. Characterization of the two-vector system in vivo
3.3.1. Thymulin and hGFP expression in the rat brain
Two days post i.c.v. injection the ETV, but not the CTV, system
markedly increased thymulin levels in the cerebrospinal fluid (CSF)
(Fig. 4A). Two days after i.c.v. injection, the ETV system selectively
transduced the ependymal cell layer, expressing high levels of hGFP
fluorescence. The expression of hGFP in the ependymal cell layer of
animals i.c.v. injected with the ETV system reached maximal intensity
in the LV (lateral ventricle) and third ventricle (3 V) from post injection
day 2 until day 7, progressively fading afterwards (Fig. 4B). On post
injection day 14 hGFP fluorescence in the ependymal cell layer of the
3 V, but not the LV, was still detectable. On post injection day 21
fluorescence was no longer detectable in the cerebral ventricles
(Fig. 4B).
3.3.2. Serum thymulin regulatability
As expected Tx induced a sharp fall in circulating thymulin levels in
the animals. Intramuscular injection of the ETV system in young Tx rats
induced a cumulative increase in serum thymulin levels which by post
injection day 10, reached 300% higher levels than in pre Tx animals,
remaining at those levels until the end of the experiment, on post
injection day 49 (last day monitored). Serum thymulin levels in Tx rats
injected with the CTV system remained at nearly undetectable levels
throughout the experiment (Fig. 5A). When the ETV system was i.m.
injected in non-Tx young rats, serum thymulin increased, reaching
maximal values around post injection day 10. When DOX was added to
the drinking water on post injection day 15, serum thymulin levels
rapidly fell to pre injection levels. When β-methasone was added to the
drinking water of the same animals on post injection day 20, basal
thymulin levels fell rapidly, reaching near non-detectable levels on day
25. Rats injected with the CTV system showed no changes in thymulin
levels until the day β-methasone was added to their drinking water,
falling to near non-detectable levels on day 25 (B).
4. Discussion
Although the prospect of implementing thymic hormone gene
therapy appears as an interesting avenue of pre-clinical research, none
of the genes coding for the known thymic peptides has been cloned. In
2002 it was suggested that a possible way to overcome this problem
could be to construct “artificial genes” coding for those thymic peptides
whose amino acid sequences are short and require no posttranslational
processing (Goya et al., 2002). This was achieved for thymulin, whose
DNA sequence was initially cloned in a bacterial plasmid (Calenda
et al., 1988). Subsequently, a DNA sequence coding for the biologically
active thymulin analog metFTS was constructed and cloned in an
adenoviral vector termed RAd-metFTS (Reggiani et al., 2006). When
i.m. administered to Tx mice and rats (which possess non-detectable
levels of circulating thymulin), RAd-metFTS induced sustained supra-
physiological serum levels of biologically active thymulin which
remained high for at least 112 days in mice and for up to 270 days in
rats. Neonatal thymulin gene therapy showed significant therapeutic
efficacy in the reproductive system of congenitally athymic female mice
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(Reggiani et al., 2006).
In the brain, chronic inflammation is thought to be a potential cause
of nigral dopaminergic neurodegeneration in Parkinson’s disease
(McGeer and McGeer 2004). In this context, it is of interest to seek
anti-inflammatory compounds active in the brain and suitable for long-
term treatments aimed at protecting nigral neurons from the deleterious
effects of pro-inflammatory insults. One such treatment could involve
the use of thymulin which is emerging as a promising anti-inflamma-
tory molecule. In effect, thymulin is an immunomodulatory peptide
(Safieh-Garabedian et al., 1992) which has been used in the past for the
treatment of certain autoimmune pathologies (Bach et al., 1984). More
recent studies suggest that thymulin possesses anti-inflammatory
activity in the central nervous system (Safieh-Garabedian et al., 2003,
2011).
In the present study, i.c.v. injection of the ETV system selectively
transduced the ependymal cell layer and markedly increased thymulin
levels in the CSF. Interestingly, adenoviral-mediated expression of
metFTS in the substantia nigra and hypothalamus of adult Tx rats had
a significantly longer duration (at least 90 days) than adenoviral-
mediated expression of the gene for GFP or E. coli β-galactosidase in
the same brain regions (Morel et al., 2006). This observation is
consistent with the anti-inflammatory activity in the brain reported
for thymulin and a thymulin analog. Nevertheless, hGFP expression
duration of the ETV system was substantially shorter in the ependymal
cell layer than the thymulin expression duration of the RAd-metFTS
administered in the brain parenchyma (Morel et al., 2006). Expression
of met-FTS by the ETV system in brain parenchyma needs to be tested.
We believe that the difference in the duration of adenovirus-mediated
transgene expression is likely to be due to normal ependymocyte
turnover rather than to the immunogenicity of our ETV vector system.
Therefore, the synthetic gene for metFTS appears as a potentially
suitable therapeutic tool for the amelioration of pathologies involving
Fig. 1. Diagrammatic representation of the genome of the bidirectional regulatable two-vector Tet-Off system expressing the genes for hGFP and metFTS—It consists of two adenovector
components. One RAd harboring the expression cassette CMV-tTA, expressing the chimeric regulatory protein tTA (Right diagram of Panel A) which binds to the TRE element of the
bidirectional regulatable promoter of RAd-(GFP-TRE-FTS) (Left diagram of Panel A) and activates it, thus inducing the expression of the transgenes for hGFP y metFTS. Panel A shows
the active system (in the absence of DOX). Panel B depicts the system now deactivated by DOX. hGFP: humanized Green Fluorescent Protein; TRE: Tetracycline responsive element;
metFTS: metFTS coding sequence; tTA: chimeric regulatory protein; PminCMV: cytomegalovirus minimal promoter; SV40pA: polyadenylation signal; ITR: inverted terminal repeats; ψ:
packaging signal.
Fig. 2. MOI-dependent hGFP expression in CHO-KI, B92 and C2C12 cells transduced by either the ETV and CTV systems—The left panels show fluorescence images corresponding to cell
lines transduced with the experimental two-vector system (ETV: RAd-(GFP-TRE-FTS) + RAd-tTA) at the indicated MOIs for 48 h. ETV fluorescence in non-transduced cells (MOI = 0)
showed no fluorescence (data not shown). Obj. 10×. The plots on the right panels show fluorescence levels, expressed as arbitrary units (a.u.), in the cell lysates at the indicated MOIs. N
value is 3 in all cases. Three separate experiments were performed for each condition. Data are expressed as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001 versus
corresponding MOI = 0 control, analyzed by one-way ANOVA with post-hoc Dunnett test.
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Fig. 3. Thymulin and hGFP expression in vitro. Upper and middle panels show the expression of thymulin and hGFP, respectively, in CHO-KI cultures exposed for two days to different
experimental conditions. Thymulin concentration was determined in the cell supernatants whereas hGFP was qualitatively assessed in cell lysates by fluorometry. Notice that DOX fully
inhibited transgene expression. N value is 3 in all cases. Results are representative of 3 independent experiments. Data are expressed as mean ± SEM. Obj, 10×; *** P < 0.001 versus
non-transduced control, analyzed by one-way ANOVA with post-hoc Tukey’s test. The lower panel shows green fluorescence images of CHO-KI cells for each condition.
Fig. 4. Thymulin and hGFP expression in the brain—Panel A shows CSF thymulin levels two days after injection of the CTV and ETV system (N = 4/group). Data are expressed as
mean ± SEM. * P < 0.05 versus corresponding CTV-injected control, analyzed by unpaired Student's t-test. Panel B shows the time-course of hGFP expression in the ependymal cell
layer of the LV (upper images) and 3 V (lower images) of rats injected with the ETV system. In the 3 V, fluorescence in the processes of transduced tanycytes can be observed. LV = lateral
ventricle; 3V = third ventricle. Obj, 20×.
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acute and chronic brain inflammation.
The longer duration of thymulin expression in muscle is probably
due to the anti-inflammatory activity of thymulin which prevented the
immune system of the vector-injected animals from mounting a
destructive response against the transduced muscle cells. The same
rationale could explain the long-term persistence of high concentrations
of recombinant metFTS in the circulation of RAd-metFTS-injected Tx
rodents (Reggiani et al., 2006).
In this regard, it should be pointed out that the duration of
transduction and transgene expression is shorter when the ETV system
is delivered i.c.v., compared with the i.m. administration. We can only
be certain that a markedly long-term expression of the met-FTS
transgene occurs in muscle. This suggests that short-term i.c.v. thymu-
lin gene therapy would be suitable for an acute inflammatory condition
e.g. encephalitis. Whereas, based on its longer duration, i.m. adminis-
tration would be the best choice for a long-term therapy, aimed at
treating a rather chronic pathology. Expression of met-FTS in other
tissues needs to be tested. In this context, the regulatable two-vector
system that we have constructed constitutes an improved molecular
tool for implementing thymulin gene therapy. In effect, the expression
of the reporter hGFP makes it unnecessary to determine thymulin tissue
levels for confirmation of adenovector functionality in the brain, muscle
and any other tissue where the two-vector system is injected. This is an
important advantage due to the fact that thymulin is a nonapeptide that
easily binds to other proteins in tissues which generates considerable
interference in thymulin assays in tissue extracts (Dardenne and Bach,
1975). Additionally, the reporter gene allows precise identification of
the distribution of the transduced cells in the target tissue.
The regulatability of our two-vector system constitutes a second
advantage for long-term treatments as it allows the gene therapist to
manipulate therapeutic transgene expression during the treatment
according of treatment needs. This manipulation is achieved by means
of a noninvasive procedure (addition to or removal of DOX from the
drinking water). Furthermore, in cell cultures, the regulatability of
thymulin expression by DOX can be readily and noninvasively mon-
itored by observing the changes in hGFP fluorescence in the treated
cells. The tet system was first tested in a mammalian cell system (HeLa)
by Gossen and Bujard (1992) who found that the system was functional,
and had rapid induction with efficient tetracycline uptake. It proved to
be quite appropriate for our transgenes.
We conclude that the two-vector system that we have constructed is
likely to be suitable for short and long-term treatments in animal
models (and eventually, humans) of brain and other pathologies where
acute or chronic inflammation plays a relevant etiopathogenic role.
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